NEW ORLEANS, LA—Ever since sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to have beneficial effects in patients with heart failure, there have been questions about the underlying ...

AMSTERDAM — For patients hospitalized for acute heart failure, initiating treatment with the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) before hospital discharge was safe, it appeared to ...

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video from ASN Kidney Week, Jula Inrig, MD, chief medical officer of Travere Therapeutics Inc.

Please provide your email address to receive an email when new articles are posted on . Dapagliflozin was safe and effective at 1 year among older patients with aortic stenosis and HF who underwent ...

ZENITH-CKD is the first randomized trial comparing combined SGLT2 and endothelin A inhibition in patients with chronic kidney disease. Zibotentan, a selective endothelin A receptor antagonist, may ...

Patients with chronic kidney disease (CKD), whether or not they also had diabetes, were found to have a reduced risk of hospitalization when they took dapagliflozin. Among patients with chronic kidney ...

Modern treatments for heart failure (HF) patients with low ejection fraction (EF), which indicates systolic function impairments in the cardiovascular system, may improve EF. However, data on managing ...

The sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (Farxiga) met its primary endpoint in the DELIVER phase III trial by significantly lowering the risk of cardiovascular death or ...

Dapagliflozin improved eGFR slope in patients with CKD associated with ADPKD, but it resulted in an increase in kidney volume. Dapagliflozin may exert a protective effect on kidney function in ...

Researchers found that 53% of the 78 participants in the dapagliflozin group and 30% of the 76 participants in the placebo group had MASH improvement without worsening of fibrosis. HealthDay News — ...